Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Walter A. Shaw, Ph.D, Avanti Polar Lipids, Inc.
ClinicalTrials.gov Identifier:
NCT00406536
First received: November 29, 2006
Last updated: January 11, 2013
Last verified: January 2013

November 29, 2006
January 11, 2013
January 2007
June 2012   (final data collection date for primary outcome measure)
Improvements in essential fatty acid (EFA) and choline status over a 12-month period. [ Time Frame: 12-month period ] [ Designated as safety issue: No ]
Improvements in essential fatty acid (EFA) and choline status over a 12-month period.
Complete list of historical versions of study NCT00406536 on ClinicalTrials.gov Archive Site
Improvements in growth, nutritional, and pulmonary status over an 18-month period. [ Time Frame: 18-month period ] [ Designated as safety issue: No ]
Improvements in growth, nutritional, and pulmonary status over an 18-month period.
Not Provided
Not Provided
 
Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI
Phase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CF

The purpose of this phase II research study is to evaluate the effectiveness of the next generation LYM-X-SORB™ in improving the essential fatty acid (EFA) and choline status for children and adolescents with Cystic Fibrosis (CF) and pancreatic insufficiency (PI).

Fat malabsorption is common in individuals with cystic fibrosis (CF) and pancreatic insufficiency (PI). This places them at risk for caloric, essential fatty acid, and choline deficiency, which may in turn, lead to growth failure and a poorer clinical course. The purpose of this research study is to find whether or not taking LYM-X-SORB™ over an 18-month period, every day, will correct the problem people with CF and PI have with absorbing fat and choline. Participation will help CF doctors and other healthcare professionals learn more about the potential benefits of LYM-X-SORB™ to children and adolescents with CF and PI. These benefits may include better absorption of fat, better choline status, better growth in height, weight, muscle and bone, better lungs, and improvement of health status.

The study will enroll a total of 78 participants from Children's Hospital of Philadelphia (CHOP) and from several other Cystic Fibrosis Centers. One half of the participants will be randomly picked to receive the active powder with the LYM-X-SORB™ supplement and one half will receive a placebo (with no active supplement).

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Supportive Care
  • Cystic Fibrosis
  • Pancreatic Insufficiency
  • Dietary Supplement: Lym-X-Sorb powder
    Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
  • Dietary Supplement: Placebo powder
    The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is >99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
  • Active Comparator: 1
    Intervention: Dietary Supplement: Lym-X-Sorb powder
  • Placebo Comparator: 2
    Intervention: Dietary Supplement: Placebo powder

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
110
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed as having cystic fibrosis (CF) with pancreatic insufficiency (PI)
  • Subjects aged 6 to 17 years of age
  • In usual state of good health
  • Family and subject commitment to the 18-month study protocol
  • Fecal elastase < 15µg/g stool

Exclusion Criteria:

  • Forced expiratory volume at one second, % predicted (FEV1) < 40% predicted
  • Other chronic health conditions that may affect GI absorption, growth, dietary intake, nutritional status
  • Liver disease, lung transplant, celiac disease, allergy/intolerance to wheat/gluten, pregnant
  • Participation in another CF nutrition-related intervention study
  • Regular intake of fatty acids (i.e., fish oils) or choline nutritional supplements
  • Home parenteral lipid administration (i.e., intralipids)
Both
6 Years to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00406536
DK60302, R44DK060302, 2 R44 DK60302 02A1
Not Provided
Walter A. Shaw, Ph.D, Avanti Polar Lipids, Inc.
Avanti Polar Lipids, Inc.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Walter A. Shaw, PhD Avanti Polar Lipids, Inc.
Principal Investigator: Virginia A. Stallings, MD Children's Hospital of Philadelphia
Avanti Polar Lipids, Inc.
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP